Product-specific boundary: This page explains category definitions and evidence systems. It gives no storage, excursion-disposition, or handling direction for a product. The exact current label and qualified supply-chain or pharmacy assessment govern a named approved product.
Temperature storage categories
Regulated products receive labeled conditions supported by formulation, container, and stability data. The values below are standard category examples, not directions for an unidentified or unapproved material.
| Labeled category | Standard category examples | Meaning | Product context |
|---|---|---|---|
| Frozen | −20°C ± 5°C | A defined low-temperature category in stability and distribution systems | Used for selected starting materials, intermediates, or products only when specified |
| Refrigerated | 2–8°C | A defined cold-chain category | Appears on labels for selected approved peptide products |
| Controlled room temperature | 20–25°C in USP contexts; ICH studies may include broader climatic conditions | A controlled distribution and storage category | Applies only when supported by the named product’s data and label |
| Room temperature | Jurisdiction-specific ranges, often within 15–30°C | A regulatory or compendial category whose wording varies | Cannot be inferred from a dry appearance or peptide identity |
Always verify the current product label; category names and ranges do not transfer between formulations or jurisdictions.
Cold chain
Cold chain is the traceable time–temperature history across manufacturer release, transport, distribution, dispensing or study site, and any labeled in-use phase. Monitoring systems may include calibrated data loggers, alarms, indicators, and mapped facilities. A package that looks unchanged can still have a material excursion history.
An excursion is a recorded time–temperature history outside the specified distribution condition. Its significance depends on product-specific stability data, cumulative history, container, formulation, and applicable quality procedures. This page does not supply a keep-or-discard rule.
Freeze–thaw effects
Freezing can create ice interfaces, concentrate solutes, shift apparent pH, and promote precipitation or structural change in some liquid products. Thawing does not necessarily restore the prior molecular state. Susceptibility is product-specific and cannot be inferred from appearance.
Manufacturer release → transport → distribution → dispensing or site → in-use. A time-and-temperature record spans each stage. An excursion leads to product-specific stability assessment, not a universal disposition rule.
Stability-indicating assays
Stability programs use complementary evidence such as potency or binding assays, chromatographic purity and aggregation methods, particle measurements, pH, moisture, and appearance. Forced-degradation studies can help show whether methods distinguish relevant chemical and physical changes. A visible check alone cannot establish stability.
For the related formulation science, see lyophilization, formulation, and stability and product quality and testing.
Regulatory BUD vs. labeled expiration vs. in-use period
Expiration date: Manufacturer-supported shelf-life statement for an unopened product under the labeled condition, reviewed within the product’s regulatory record.
In-use period: Product-specific period in current approved labeling triggered by first use, opening, or labeled preparation.
Beyond-use date (BUD): Date assigned to a compounded preparation within an applicable professional compounding framework using category, process, environment, storage condition, and supporting stability or sterility evidence.
These concepts have different evidence bases, triggers, and authorities. A familiar convention from one product, setting, or older compounding framework is not a universal peptide rule.
- Expiration: manufacturer data for an unopened product under labeled conditions.
- In-use period: current approved label after first use or preparation.
- Beyond-use date: assigned within an applicable compounding framework.
Light and humidity evidence
Light can contribute to oxidation or other change in susceptible residues and excipients. Moisture ingress can plasticize a dry matrix, lower its glass transition, or accelerate degradation. Product labels, packaging studies, and container-closure integrity data establish the relevant controls; this conceptual page does not translate them into handling directions.
Freeze-dried product mapping
| Product | Dry presentation confirmed in cited label | Label link |
|---|---|---|
| Cetrorelix / Cetrotide | Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. Definition source: Lyophilization, formulation, and stability primer · Glossary powder presentation | FDA and EMA records in the label index |
| Degarelix / Firmagon | Lyophilized powder presentation | FDA and EMA records in the label index |
| Enfuvirtide / Fuzeon | Lyophilized powder presentation | FDA and EMA records in the label index |
| Glucagon / GlucaGen | Lyophilized powder presentation | FDA and national-register context in the label index |
| Somatropin / Genotropin | Selected dry presentations | FDA and national-register context in the label index |
| Tesamorelin / Egrifta WR | Lyophilized powder presentation | FDA record in the label index |
This mapping confirms presentation only. It does not transfer shelf life, in-use period, preparation, or storage claims between products. The approved-product label index is a navigation aid, and reconstitution science explains why dry presentations still require product-specific evidence.
Sources
ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products (Q1A(R2)). 2003. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (Q5C). 1995. https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf
USP General Chapter
<797>Pharmaceutical Compounding — Sterile Preparations. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.WHO. WHO Technical Report Series, No. 953, Annex 5: Good Distribution Practices for Pharmaceutical Products. 2010.
FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008.
Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969–975. https://doi.org/10.1023/a:1012180707283
USP General Chapter
<659>Packaging and Storage Requirements. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.